BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Azacitidine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Azacitidine\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03850574-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT03850574)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clini
 cal Trial to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Pha
 rmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refract
 ory Acute Myeloid Leukemia\nEstimated primary completion: November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03850574
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05788679-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05788679)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects Wit
 h MDS\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05788679
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955261-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05955261)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Venetoclax in Combination With Conventional Chemotherapy in Pediatric 
 Patients With Acute Myeloid Leukemia\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595
 5261
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06066905-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase na readout est. (NCT06066905)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of Chidamide With AZA in MRD Positive AML After Transplant\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06066905
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06190067-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06190067)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Azacitidine Plus PD-1 Therapy fo
 r R/R Hodgkin Lymphoma\nEstimated primary completion: December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06190067
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377085-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06377085)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: Repurposing 5-Azacytidine for th
 e Treatment of Muscle Contractures in Children With Cerebral Palsy\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06377085
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06429449-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06429449)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Mitoxan
 trone for Venetoclax Resistant Acute Myeloid Leukemia\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06429449
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783790-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06783790)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Avaprit
 inib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed
  AML After Allo-HSCT\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06783790
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000617-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07000617)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: A Phase II Study of Dexamethason
 e\, Azacitidine\, Pegaspargase and Tislelizumab Plus Radiotherapy for Pati
 ents With Stage I/II Extranodal NK/T-cell Lymphoma\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07000617
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303660-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07303660)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase
  1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07303660
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05376111-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05376111)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Study of Venetoclax Combined Wit
 h Azacitidine Regimen in Newly Diagnosed T-ALL Patients\nEstimated primary
  completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05376111
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220162-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06220162)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VAC Reg
 imen for AML Patients Who Failed to Response to VA Regimen\nEstimated prim
 ary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06220162
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635681-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06635681)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficac
 y of Venetoclax Combined With Intensive Chemotherapy in Different Subgroup
 s of AML\nEstimated primary completion: 1 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06635681
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757855-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06757855)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: Olverembatinib Combined With V
 enetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML\nEstim
 ated primary completion: 1 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06757855
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858618-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06858618)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: FCN-338 in Combination With Azac
 itidine or Chemotherapy in Myeloid Neoplasms\nEstimated primary completion
 : 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/az
 acitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06858618
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588922-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04588922)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in P
 atients With Hematologic Malignancies and High-Risk Newly Diagnosed AML\nE
 stimated primary completion: 30 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04588922
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05958719-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05958719)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Chidamide in Combination With Az
 acitidine\, Liposomal Mitoxantrone\, and Prednisone (CAMP Regimen) for the
  Treatment of Previously Untreated Nodal TFH Cell Lymphoma\nEstimated prim
 ary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05958719
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06451861-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06451861)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Randomi
 zed Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy
  or AB-14 for ND AML\nEstimated primary completion: 30 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06451861
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00392353-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT00392353)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Vorin
 ostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes 
 or Acute Myeloid Leukemia\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT00392353
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04128501-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT04128501)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Pos
 t-Transplant Setting\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04128501
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05074355-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05074355)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Study of Venetoclax and Azacitid
 ine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms\nEstimated p
 rimary completion: 31 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05074355
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05230680-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05230680)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: Azacitidine-CHOP for Patients 
 With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05230680
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05355051-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05355051)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: A Phase II Study of the Combinat
 ion of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodg
 kin's Lymphoma\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05355051
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584761-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05584761)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Unrel
 ated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatm
 ent for Advanced MDS\,CMML-2 and sAML\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitid
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05584761
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345365-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 3 readout est. (NCT06345365)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: MA+AZA 
 Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06345365
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06502145-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06502145)
DESCRIPTION:Azacitidine\, phase 1\, Myelodysplastic Syndromes.\nStudy: Iada
 demstat With Hypomethylating Agent in Patients With Myelodysplastic Syndro
 me\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06502145
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486479-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07486479)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax\, Azacitidine\, and Mitoxantrone Hydrochloride Liposome Versus Idarubi
 cin and Cytarabine in Newly Diagnosed AML\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07486479
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05001828-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 1 readout est. (NCT05001828)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study o
 f ADI-PEG 20\, Venetoclax and Azacitidine in Acute Myeloid Leukemia\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05001828
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317403-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 1 readout est. (NCT05317403)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax to Augment Epigenetic Modification and Chemotherapy\nEstimated primary
  completion: January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05317403
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177067-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06177067)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study o
 f Revumenib\, Azacitidine\, and Venetoclax in Pediatric and Young Adult Pa
 tients With Refractory or Relapsed Acute Myeloid Leukemia\nEstimated prima
 ry completion: January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06177067
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384261-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06384261)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and A
 zacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy\nEstima
 ted primary completion: January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06384261
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773208-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06773208)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
 \nEstimated primary completion: January 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06773208
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04801797-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Azacitidine: Phase 2 readout est. (NCT04801797)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax + Azacitidine vs. Induction Chemotherapy in AML\nEstimated primary com
 pletion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04801797
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754540-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06754540)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Azaciti
 dine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Po
 st-transplant Relapse Prevention.\nEstimated primary completion: 1 January
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067545
 40
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06886425-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Azacitidine: Phase na readout est. (NCT06886425)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: Involv
 ement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidin
 e Treatment of Patients With Hematologic Malignancies\nEstimated primary c
 ompletion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06886425
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06763341-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06763341)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase
  1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leu
 kemia\nEstimated primary completion: 16 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06763341
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03862157-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT03862157)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azaci
 tidine\, Venetoclax\, and Pevonedistat in Treating Patients With Newly Dia
 gnosed Acute Myeloid Leukemia\nEstimated primary completion: 31 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03862157
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04086264-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04086264)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: IMGN6
 32 as Monotherapy or With Venetoclax and/or Azacitidine for Participants W
 ith CD123-Positive Acute Myeloid Leukemia\nEstimated primary completion: F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04086264
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Azacitidine: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEstimated prim
 ary completion: February 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03383575-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Azacitidine: Phase 2 readout est. (NCT03383575)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Azaciti
 dine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic 
 Syndrome\nEstimated primary completion: 28 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03383575
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428969-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05428969)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy to Assess Safety\, Tolerability and Preliminary Efficacy of Bexmarilima
 b in Combination With Standard of Care in Patients With Hematological Mali
 gnancies\nEstimated primary completion: March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05428969
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357182-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06357182)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Iadadem
 stat in Combination With Azacitidine and Venetoclax in Treating Newly Diag
 nosed Acute Myeloid Leukemia\nEstimated primary completion: 8 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06357182
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated
  primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554406-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05554406)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing
  New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diag
 nosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)\nE
 stimated primary completion: 31 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05554406
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388563-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07388563)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: Azacitidine and Abatacept in Rel
 apsed or Refractory T-Cell Lymphoma\nEstimated primary completion: 31 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07388
 563
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012447-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07012447)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Venetoclax + Azacytidine for New
 ly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations\nEstimated prim
 ary completion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07012447
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498973-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06498973)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Tagraxo
 fusp and Azacitidine for Maintenance Treatment in Patients With CD123 Posi
 tive AML and MDS Following Donor Hematopoietic Cell Transplant\nEstimated 
 primary completion: 25 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06498973
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03586609-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Azacitidine: Phase 2 readout est. (NCT03586609)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax\, Cladribine\, Low Dose Cytarabine\, and Azacitidine in Treating Patie
 nts With Previously Untreated Acute Myeloid Leukemia\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03586609
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891068-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Azacitidine: Phase 2 readout est. (NCT04891068)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: BRE-04: Window of Opportunity Tr
 ial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast C
 ancer\nEstimated primary completion: May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04891068
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04150887-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Azacitidine: Phase 1 readout est. (NCT04150887)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Cusatuz
 umab in Combination With Background Therapy for the Treatment of Participa
 nts With Acute Myeloid Leukemia\nEstimated primary completion: 15 May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04150887
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07548710)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study o
 f SA+X in the Treatment of Newly Diagnosed AML\nEstimated primary completi
 on: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07548710
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06656494-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06656494)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: ICP-248
  in Combination With Azacitidine for the Treatment in Patients With Myeloi
 d Malignancies\nEstimated primary completion: June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06656494
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Pha
 se 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Hori
 zen-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06429098-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06429098)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study o
 f A Venetoclax-based\, Anthracycline-free Regimen in Newly Diagnosed CBFβ
 ::MYH11(+) AML\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06429098
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07094464-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07094464)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Mainten
 ance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After T
 ransplantation\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07094464
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090786-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Azacitidine: Phase na readout est. (NCT06090786)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: Kineti
 cs and Impact on Survival of MRD in AML Patients Receiving Azacitidine and
  Venetoclax\nEstimated primary completion: July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06090786
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06159491-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06159491)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: Pacritinib in CMML\nEstimated 
 primary completion: July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06159491
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06372717-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06372717)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study
  to Investigate APL-4098 Alone and in Combination in Adults With AML or MD
 S\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06372717
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05772273-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Azacitidine: Phase na readout est. (NCT05772273)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: PD-1 I
 nhibitor\, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT\nEs
 timated primary completion: 1 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05772273
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445907-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06445907)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Phase I
  Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory 
 Acute Myeloid Leukemia\nEstimated primary completion: 1 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06445907
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04227847-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270704
DTEND;VALUE=DATE:20270705
SUMMARY:Azacitidine: Phase 1 readout est. (NCT04227847)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Safet
 y Study of SEA-CD70 in Patients With Myeloid Malignancies\nEstimated prima
 ry completion: 4 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04227847
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03843528-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Azacitidine: Phase 1 readout est. (NCT03843528)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Vorinos
 tat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation\nE
 stimated primary completion: 30 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03843528
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532552-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06532552)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Compari
 son of VA (Venetoclax\, Azacitidine)\, VACl (VA\, Cladribine)\, VACh (VA\,
  Chidamide)\, and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid L
 eukemia\nEstimated primary completion: 1 August 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06532552
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651229-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270805
DTEND;VALUE=DATE:20270806
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06651229)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study
  of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myel
 odysplastic Neoplasms\nEstimated primary completion: 5 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06651229
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616636-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06616636)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase
  Ib Study of Rezatapopt in Combination With Azacitidine in Patients With T
 P53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodyspl
 astic Syndrome)\nEstimated primary completion: 27 August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06616636
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132684-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07132684)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Compari
 son of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemi
 a Patients\nEstimated primary completion: 30 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07132684
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761533-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07761533)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: PBSS1
 113 in Combination With Azacitidine to Treat Patients With AML/MDS\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07761533
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743112-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07743112)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase
  2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Ne
 wly Diagnosed Acute Myeloid Leukemia\nEstimated primary completion: 1 Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7743112
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813390-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07813390)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Homohar
 ringtonine\, Lisaftoclax\, and Azacitidine for AML After Venetoclax-Based 
 Therapy Failure\nEstimated primary completion: 1 September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07813390
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03326310-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270904
DTEND;VALUE=DATE:20270905
SUMMARY:Azacitidine: Phase 1 readout est. (NCT03326310)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: Selumetinib and Azacitidine in H
 igh Risk Chronic Blood Cancers\nEstimated primary completion: 4 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0332631
 0
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04734990-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270911
DTEND;VALUE=DATE:20270912
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04734990)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: Seclidemstat and Azacitidine f
 or the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leu
 kemia\nEstimated primary completion: 11 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04734990
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03683433-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Azacitidine: Phase 2 readout est. (NCT03683433)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Enaside
 nib and Azacitidine in Treating Patients With Recurrent or Refractory Acut
 e Myeloid Leukemia and IDH2 Gene Mutation\nEstimated primary completion: 2
 0 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aza
 citidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03683433
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02530463-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT02530463)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Nivolumab and/or Ipilimumab With
  or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
 \nEstimated primary completion: 30 September 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02530463
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03471260-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT03471260)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Ivosi
 denib and Venetoclax With or Without Azacitidine in Treating Patients With
  IDH1 Mutated Hematologic Malignancies\nEstimated primary completion: 30 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacit
 idine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03471260
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401097-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05401097)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: IDH Tar
 geted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatme
 nt of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensiv
 e Induction Therapy (I- DATA Study)\nEstimated primary completion: 30 Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5401097
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514936-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07514936)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patient
 s With Acute Myeloid Leukaemia\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075149
 36
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722767-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07722767)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase
  1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML
  Patients\nEstimated primary completion: 30 September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07722767
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06511882-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06511882)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Discont
 inuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06511882
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06634394-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06634394)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: APVO436
  Phase 1b/2 Study in Patients With Newly Diagnosed AML\nEstimated primary 
 completion: October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06634394
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163793-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07163793)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Pilot S
 tudy of Reduced Venetoclax Exposure\nEstimated primary completion: October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071637
 93
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486726-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07486726)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Aclar
 ubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myel
 oid Leukemia\nEstimated primary completion: October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07486726
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07632170-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Azacitidine: Phase na readout est. (NCT07632170)
DESCRIPTION:Azacitidine\, phase na.\nStudy: The Efficacy and Safety of Seli
 nisole Combined With Azacitidine and Venetoclax in the Treatment of Newly 
 Diagnosed High-risk Myeloid Tumors With TP53 Mutations\nEstimated primary 
 completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07632170
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504459-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06504459)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax in Combination With Cladribine and Cytarabine Alternating With Azaciti
 dine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML an
 d Active Signaling Mutated AML\nEstimated primary completion: 11 October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06504459
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907057-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Azacitidine: Phase 3 readout est. (NCT05907057)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Open
 -label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adu
 lt Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Inelig
 ible for Intensive Induction Chemotherapy.\nEstimated primary completion: 
 15 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05907057
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686108-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06686108)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Demethylating Agents Combined Wi
 th Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Tr
 ansplant Relapse Prevention\nEstimated primary completion: 30 October 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06686108
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497062-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06497062)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Phase I
 I Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newl
 y Diagnosed Acute Myeloid Leukemia\nEstimated primary completion: 31 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0649
 7062
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06523556-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06523556)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: Axatilimab With or Without Aza
 citidine for the Treatment of Patients With Advanced Phase Myeloproliferat
 ive Neoplasms\, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overl
 ap or High Risk Chronic Myelomonocytic Leukemia\nEstimated primary complet
 ion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06523556
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044687-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Azacitidine: Phase 4 readout est. (NCT07044687)
DESCRIPTION:Azacitidine\, phase 4\, Acute Myeloid Leukemia.\nStudy: Study t
 o Assess Adverse Events and Change in Disease Activity of Oral Venetoclax 
 in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in N
 ewly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Ar
 e Ineligible for Standard Induction Therapy in India\nEstimated primary co
 mpletion: November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07044687
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04256317-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT04256317)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Mul
 ti-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neopla
 sm Alone or in Combination With Venetoclax in AML (AZTOUND Study)\nEstimat
 ed primary completion: 1 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04256317
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465953-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Azacitidine: Phase 3 readout est. (NCT06465953)
DESCRIPTION:Azacitidine\, phase 3\, Myelodysplastic Syndromes.\nStudy: Ivos
 idenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients Wit
 h Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With a
 n IDH1 Mutation\nEstimated primary completion: 1 November 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06465953
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04581512-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04581512)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  to Evaluate the Safety and Tolerability of EP0042\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04581512
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470841-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06470841)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: CHG Com
 bined With Venetoclax and Azacytidine in Newly Diagnosed AML\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06470841
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax
  + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07255872
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678933-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Azacitidine: Phase 3 readout est. (NCT05678933)
DESCRIPTION:Azacitidine\, phase 3.\nStudy: AC-CHOP Versus CHOP in Patients 
 With Previously Untreated PTCL-TFH\nEstimated primary completion: 1 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0567
 8933
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548230-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06548230)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Pha
 se 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Withou
 t Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute My
 elogenous Leukemia (AML)\nEstimated primary completion: 1 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06548230
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744556-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06744556)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: HAV Ver
 sus DAV/IAV Induction Regimen in Elderly Patients With AML\nEstimated prim
 ary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06744556
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304011-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07304011)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutasi
 denib With Azacitidine Followed by Olutasidenib Maintenance for the Treatm
 ent of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatmen
 t With Venetoclax Plus a Hypomethylating Agent\nEstimated primary completi
 on: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07304011
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533761-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06533761)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Eganeli
 sib as Monotherapy and in Combination With Cytarabine in Relapsed/Refracto
 ry AML/HR-MDS and in Combination With Azacitidine in Previously Untreated 
 HR-MDS\nEstimated primary completion: 15 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06533761
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06386302-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Azacitidine: Phase na readout est. (NCT06386302)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: Chidam
 ide\, Venetoclax\, and Azacitidine for Newly Diagnosed Acute Myeloid Leuke
 mia\nEstimated primary completion: 30 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06386302
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03874052-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT03874052)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Ruxolit
 inib in Combination With Venetoclax With and Without Azacitidine in Treati
 ng Patients With Relapsed or Refractory Acute Myeloid Leukemia\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03874052
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04493138-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04493138)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: Azacitidine and Quizartinib fo
 r the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloprolif
 erative Neoplasm With FLT3 or CBL Mutations\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/az
 acitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04493138
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270200-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05270200)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Singl
 e Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of
  Acute Myelogenous Leukemia Relapse\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 270200
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05365035-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05365035)
DESCRIPTION:Azacitidine\, phase 2\, Myelodysplastic Syndromes.\nStudy: A Ph
 ase II Study of Cladribine and Low Dose Cytarabine in Combination With Ven
 etoclax\, Alternating With Azacitidine and Venetoclax\, in Patients With H
 igher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-ri
 sk Myelodysplastic Syndromes With Excess Blasts\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05365035
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554393-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05554393)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Compari
 ng Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Ve
 netoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermed
 iate Risk AML (A MyeloMATCH Treatment Trial)\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 zacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05554393
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05641259-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT05641259)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study
  to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azaciti
 dine In Subjects With AML\, MDS\, CMML\nEstimated primary completion: 31 D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05641259
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548983-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07548983)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Ruxolit
 inib With Azacitidine Maintenance for the Treatment of Patients With Acute
  Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transp
 lantation\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07548983
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573670-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07573670)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: A Phase 2 Study of Bcl-2 Inhibit
 or Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leu
 kemia\nEstimated primary completion: 31 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07573670
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748455-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07748455)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: HMA-Ven
 etoclax Induction in Newly Diagnosed AML\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaci
 tidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07748455
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828535-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07828535)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Liposom
 al Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly
  or Unfit AML\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07828535
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862517-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07862517)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing
  the Investigational Medication Combination of Azacitidine\, Venetoclax\, 
 and Quizartinib Compared to the Usual Treatment of Cytarabine\, Daunorubic
 in\, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leuke
 mia (A MyeloMATCH Treatment Trial)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 62517
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885397-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07885397)
DESCRIPTION:Azacitidine\, phase 1/2\, Myelodysplastic Syndromes.\nStudy: So
 nrotoclax Plus Azacitidine in Patients With MDS-IB2\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07885397
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392242-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07392242)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of the Combination of Ivosidenib\, Azacitidine\, and Venetoclax Followed 
 by Ivosidenib Alone in People With Acute Myeloid Leukemia\nEstimated prima
 ry completion: January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07392242
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706959-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07706959)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: New Genotype-guided Treatment 
 in Newly Diagnosed PTCL\nEstimated primary completion: January 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07706959
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06778902-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06778902)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: AZA Combined with R-GemOx for El
 derly DLBCL Patients\nEstimated primary completion: 1 January 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06778902
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372352-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07372352)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Zeprumetostat\, Azacitidine Comb
 ined With Lipo-MIT in R/R PTCL\nEstimated primary completion: 15 January 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07372352
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265545-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Azacitidine: Phase na readout est. (NCT06265545)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: Multic
 enter\, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid
  Leukemia\nEstimated primary completion: 30 January 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06265545
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389616-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07389616)
DESCRIPTION:Azacitidine\, phase 2/3.\nStudy: A Clinical Trial of Cidabenami
 ne Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Pe
 ripheral T-Cell Lymphoma\nEstimated primary completion: 1 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07389616
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407660-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07407660)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Shorten
 ed Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy i
 n Elderly or Frail Patients With AML Patients Treated With Azacitidine Plu
 s Venetoclax\nEstimated primary completion: 1 February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07407660
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07439211-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07439211)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Assessi
 ng PI3K Gamma Inhibition With Azacitidine\, Venetoclax and Eganelisib in P
 atients With Acute Myeloid Leukemia\nEstimated primary completion: 1 Febru
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 39211
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456463-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06456463)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults W
 ith Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive C
 hemotherapy\nEstimated primary completion: 9 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456463
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201066-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05201066)
DESCRIPTION:Azacitidine\, phase 2\, Myelodysplastic Syndromes.\nStudy: Roll
 -over Study for Patients Who Have Completed a Prior Novartis-sponsored Sab
 atolimab (MBG453) Study and Are Judged by the Investigator to Benefit From
  Continued Treatment With Sabatolimab.\nEstimated primary completion: 14 F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05201066
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03850418-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Azacitidine: Phase 2 readout est. (NCT03850418)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Azaciti
 dine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Trans
 plant\nEstimated primary completion: 20 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03850418
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404332-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07404332)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: 5-Azacitidine Plus PD-1/PD-L1 In
 hibitor With PD-1/PD-L1 Refractory Tumors\nEstimated primary completion: 2
 8 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07404332
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06896110-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06896110)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: Intrathecal Azacitidine and Nivo
 lumab in Patients With Recurrent High-grade Glioma\nEstimated primary comp
 letion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 zacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06896110
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071155-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280305
DTEND;VALUE=DATE:20280306
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07071155)
DESCRIPTION:Azacitidine\, phase 1\, Myelodysplastic Syndromes.\nStudy: Mome
 lotinib in Combination With Hypomethylating Agent for Chronic Phase Myelod
 ysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutr
 ophilic Leukemia\nEstimated primary completion: 5 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07071155
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469046-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07469046)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAH vs 
 VA in Newly Diagnosed Elderly AML\nEstimated primary completion: 31 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746904
 6
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507825-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07507825)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Explora
 tory Study of Venetoclax\, Homoharringtonine\, Azacitidine Plus G-CSF for 
 Newly Diagnosed AML (VHAG)\nEstimated primary completion: 31 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07507825
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018752-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07018752)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: A Platform Trial Evaluating Ne
 w Drugs or Combination in R/R Peripheral T-cell Lymphomas\nEstimated prima
 ry completion: April 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07018752
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514832-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07514832)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA-CIG 
 Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Pro
 spective Single-Arm Trial\nEstimated primary completion: 1 April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07514832
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779031-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07779031)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Sin
 gle-Arm\, Open Phase I Clinical Study of Selinexor in Combination With Aza
 citidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT\n
 Estimated primary completion: 30 April 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07779031
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131059-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Azacitidine: Phase na readout est. (NCT07131059)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: MRD-po
 sitive AML Clinical Study\nEstimated primary completion: 10 May 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07131059
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046182-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280526
DTEND;VALUE=DATE:20280527
SUMMARY:Azacitidine: Phase 4 readout est. (NCT07046182)
DESCRIPTION:Azacitidine\, phase 4.\nStudy: Clinical Study of CEP+Dasatinib 
 + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight\nE
 stimated primary completion: 26 May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07046182
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664839-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07664839)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study o
 n the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly
  Diagnosed AML With NPM1 or IDH1/IDH2 Mutations\nEstimated primary complet
 ion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aza
 citidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07664839
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05404906-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT05404906)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: AZA +
  Venetoclax as Maintenance Therapy in Younger Adults With AML in First Rem
 ission\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05404906
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668558-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06668558)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated prima
 ry completion: June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06668558
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471841-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07471841)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutasi
 denib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received V
 enetoclax\nEstimated primary completion: June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07471841
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642453-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07642453)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA-CAG 
 Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed
  Acute Myeloid Leukemia.\nEstimated primary completion: 1 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07642453
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317000-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05317000)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: 5-Azacytidine and/or Nivolumab i
 n Resectable HPV-Associated HNSCC\nEstimated primary completion: 30 June 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05317000
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05834244-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azacitidine: Phase 1 readout est. (NCT05834244)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase
  Ib Trial of Azacitidine\, Venetoclax and Allogeneic NK Cells for Acute My
 eloid Leukemia (ADVENT-AML)\nEstimated primary completion: 30 June 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05834244
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605949-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07605949)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Revumen
 ib\, Azacitidine\, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML\
 nEstimated primary completion: July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07605949
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05292664-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280702
DTEND;VALUE=DATE:20280703
SUMMARY:Azacitidine: Phase 1 readout est. (NCT05292664)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax Basket Trial for High Risk Hematologic Malignancies\nEstimated primary
  completion: 2 July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05292664
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05520567-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05520567)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of Gilteritinib\, Venetoclax and Azacitidine as a Combined Treatment fo
 r People Newly Diagnosed With Acute Myeloid Leukemia\nEstimated primary co
 mpletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05520567
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06664879-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06664879)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: ALLG 
 AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and 
 Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm\, Precision-b
 ased\, Recursive\, Platform Trial\nEstimated primary completion: 31 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06664879
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746245-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07746245)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: The Efficacy of CAPCT in Patient
 s With PTCL\nEstimated primary completion: 31 July 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07746245
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771130-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04771130)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of BGB-11417 in Participants With Myeloid Malignancies\nEstimated prima
 ry completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04771130
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501120-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04501120)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Pa
 tients Relapsed/Refractory AML\nEstimated primary completion: September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04501120
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140487-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04140487)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azaci
 tidine\, Venetoclax\, and Gilteritinib in Treating Patients With Recurrent
 /Refractory FLT3-Mutated Acute Myeloid Leukemia\, Chronic Myelomonocytic L
 eukemia\, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplas
 m\nEstimated primary completion: 1 September 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04140487
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06176027-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06176027)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: Azacytidine Plus CAOLD Regimen
  in Relapsed/Refractory Peripheral T-Cell Lymphomas\nEstimated primary com
 pletion: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06176027
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159620-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07159620)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Venetoclax Combined With Azaciti
 dine\, Chidamide\, Vindesine\, and Dexamethasone in Newly Diagnosed ETP-AL
 L Like Patients\nEstimated primary completion: 1 September 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07159620
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679334-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07679334)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: Phase I Trial of Pacritinib in C
 ombination With Venetoclax and Azacitidine for the Treatment of Accelerate
 d and Blast Phase Myeloproliferative Neoplasms\nEstimated primary completi
 on: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07679334
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932873-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07932873)
DESCRIPTION:Azacitidine\, phase 2/3\, Myelodysplastic Syndromes.\nStudy: So
 nrotoclax in Combination With Azacitidine for Previously Untreated Higher-
 risk Myelodysplastic Syndromes\nEstimated primary completion: 1 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793287
 3
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425808-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07425808)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: FLT3-
 ITD Targeted Therapy in Fit AML Patients\nEstimated primary completion: 1 
 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07425808
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557421-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06557421)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: De-Esca
 lation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML 
 Responding Patients\nEstimated primary completion: 1 November 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06557421
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05849662-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05849662)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: A Phase I/II Study of Trametin
 ib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocyt
 ic Leukemia\nEstimated primary completion: December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05849662
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06014489-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06014489)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Trial
  to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine i
 n Adult Patients With Newly Diagnosed AML\nEstimated primary completion: D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06014489
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060001-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07060001)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficac
 y of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Le
 ukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker\nEstima
 ted primary completion: December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07060001
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646821-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281211
DTEND;VALUE=DATE:20281212
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07646821)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Pha
 se 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML W
 ith TP53 Mutations\nEstimated primary completion: 11 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07646821
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841952-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Azacitidine: Phase na readout est. (NCT06841952)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: Study 
 of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Tr
 eatment Naïve Participants With Acute Myeloid Leukemia\nEstimated primary
  completion: 15 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06841952
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06397027-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT06397027)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: A Phase I Study Investigating th
 e Combination of the Ziftomenib\, Venetoclax and Azacitidine in Pediatric 
 Relapsed and Refractory Acute Leukemias\nEstimated primary completion: 31 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacit
 idine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06397027
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148180-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07148180)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Mul
 ti-Site Break Through Cancer Trial: Targeting Measurable Residual Disease 
 in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp\
 , Azacitidine\, and Venetoclax\nEstimated primary completion: 31 December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0714818
 0
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148947-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07148947)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Pacritinib With Standard of Care
  Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Ce
 ll Transplant for Patients With Accelerated and Blast Phase Myeloprolifera
 tive Neoplasms\nEstimated primary completion: 31 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07148947
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177079-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07177079)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: High-do
 se Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Ve
 netoclax in Acute Myeloid Leukemia (AML)\nEstimated primary completion: 31
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaci
 tidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07177079
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407140-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07407140)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAG Ver
 sus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-
 Mutated AML\nEstimated primary completion: 1 February 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07407140
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782542-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06782542)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutasi
 denib\, Venetoclax\, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute
  Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy\n
 Estimated primary completion: 31 March 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06782542
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696183-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06696183)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilteri
 tinib in Combination With Venetoclax and Azacitidine for AML Patients With
  FLT3 Mutations Ineligible for Intensive Treatment\nEstimated primary comp
 letion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 zacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06696183
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMA
 TCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment
  Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screeni
 ng Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317649-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06317649)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute My
 eloid Leukemia (AML) (A MyeloMATCH Treatment Trial)\nEstimated primary com
 pletion: 15 May 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06317649
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07635485-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Azacitidine: Phase na readout est. (NCT07635485)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: VA Ind
 uction and Bridging Transplantation for Hypoplastic/Secondary AML\nEstimat
 ed primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07635485
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542912-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Azacitidine: Phase na readout est. (NCT07542912)
DESCRIPTION:Azacitidine\, phase na.\nStudy: Sintilimab\, Chidamide\, and Az
 acitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma\nEstimate
 d primary completion: 1 June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07542912
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047183-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07047183)
DESCRIPTION:Azacitidine\, phase 2\, Myelodysplastic Syndromes.\nStudy: Clin
 ical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Pri
 or to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk
  Myelodysplastic Syndromes\nEstimated primary completion: 30 June 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07047183
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762508-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Azacitidine: Phase na readout est. (NCT07762508)
DESCRIPTION:Azacitidine\, phase na\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of VABu Conditioning Regimen in Allo-HSCT for AML Patients\nEstimated pr
 imary completion: July 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07762508
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471946-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06471946)
DESCRIPTION:Azacitidine\, phase 1/2\, Myelodysplastic Syndromes.\nStudy: VA
  Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS\nEstimated pri
 mary completion: 1 September 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06471946
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754799-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07754799)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Rando
 mized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acu
 te Myeloid Leukemia\nEstimated primary completion: 30 September 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07754799
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755202-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07755202)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilteri
 tinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed
 /Refractory Leukemia\nEstimated primary completion: 1 October 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07755202
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691450-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291124
DTEND;VALUE=DATE:20291125
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07691450)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: Belinostat in Combination With A
 zacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-ce
 ll Lymphoma\nEstimated primary completion: 24 November 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07691450
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651163-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07651163)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Compa
 ring the Efficacy of LDA\, LHAA\, and LA Regimens in Young Adults With Int
 ermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Che
 motherapy\nEstimated primary completion: December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07651163
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651176-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07651176)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Compa
 ring the Efficacy of the LDA\, LHAA\, and DA Regimens in Young Adults With
  Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy\nEsti
 mated primary completion: December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07651176
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925190-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07925190)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study
  Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Unt
 reated Acute Myeloid Leukemia (AML) Patients\nEstimated primary completion
 : December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azac
 itidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07925190
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522801-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07522801)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: A Precision Medicine Trial for P
 atients With Relapsed or Refractory T Cell ALL\nEstimated primary completi
 on: 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07522801
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493330-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291212
DTEND;VALUE=DATE:20291213
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07493330)
DESCRIPTION:Azacitidine\, phase 1/2.\nStudy: Genotype-guided Targeted Agent
 s Plus EZH2i for Primary Refractory PTCL\nEstimated primary completion: 12
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaci
 tidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07493330
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508982-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291212
DTEND;VALUE=DATE:20291213
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07508982)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase
 1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML\nEstimated prim
 ary completion: 12 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07508982
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276698-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07276698)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Clinical Study on Maintenance Th
 erapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoie
 tic Stem Cell Transplantation for NK/T-cell Lymphoma\nEstimated primary co
 mpletion: 30 December 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07276698
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase
  2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subj
 ects With R/R AML\nEstimated primary completion: 31 December 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598578-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07598578)
DESCRIPTION:Azacitidine\, phase 1.\nStudy: An Open-label\, Single-arm\, Mul
 ticenter Phase II Clinical Study of Azacitidine\, Chidamide Combined With 
 PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Periphera
 l T-cell Lymphoma.\nEstimated primary completion: 1 January 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07598578
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735184-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Azacitidine: Phase 1 readout est. (NCT05735184)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study
  to Investigate the Safety and Tolerability of Ziftomenib in Combination W
 ith Venetoclax/Azacitidine\, Venetoclax\, 7+3\, or 7+3+Quizartinib in Pati
 ents With AML\nEstimated primary completion: April 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05735184
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478991-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07478991)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Azacyti
 dine\, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Pa
 tients (VENP-A-QUI)\nEstimated primary completion: April 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07478991
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770698-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07770698)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acut
 e Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia\nEstimated prim
 ary completion: 30 April 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07770698
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07078591-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07078591)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax-containing Therapy Combined With Microtransplant for Newly Diagnosed A
 ML\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07078591
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672262-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07672262)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA Cons
 olidation in Intermediate-Risk AML\nEstimated primary completion: 1 June 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07672262
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320235-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300617
DTEND;VALUE=DATE:20300618
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07320235)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: Imetels
 tat Combinations in Relapsed AML\nEstimated primary completion: 17 June 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07320235
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645469-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300719
DTEND;VALUE=DATE:20300720
SUMMARY:Azacitidine: Phase 1 readout est. (NCT07645469)
DESCRIPTION:Azacitidine\, phase 1\, Acute Myeloid Leukemia.\nStudy: FH-WT1-
 E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Dis
 ease Positive Acute Myeloid Leukemia\nEstimated primary completion: 19 Jul
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07645
 469
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442216-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300721
DTEND;VALUE=DATE:20300722
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05442216)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Tagraxo
 fusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML Afte
 r Hypomethylating Agents\nEstimated primary completion: 21 July 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05442216
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686965-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300810
DTEND;VALUE=DATE:20300811
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07686965)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Lisafto
 clax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell
  Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relaps
 e\nEstimated primary completion: 10 August 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07686965
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07433023-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07433023)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: tSCS and 5-Azacitidine for Enhan
 ced Motor Outcomes in Cerebral Palsy\nEstimated primary completion: 31 Aug
 ust 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 33023
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07434492-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07434492)
DESCRIPTION:Azacitidine\, phase 2.\nStudy: Smart AFO and 5-Azacitidine to E
 nhance Mobility in Children With Cerebral Palsy\nEstimated primary complet
 ion: 31 August 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07434492
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904106-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05904106)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With N
 ewly Diagnosed NPM1 Mutated AML\nEstimated primary completion: September 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05904106
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598384-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Azacitidine: Phase 2 readout est. (NCT06598384)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA as M
 aintenance Therapy Post Allo-HSCT in MDS and AML\nEstimated primary comple
 tion: September 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06598384
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082452-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07082452)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Multi
 center Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposu
 re To Seven Days Versus Standard Continuous Venetoclax Exposure Combined W
 ith Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia W
 ho Are Ineligible for Intensive Induction\nEstimated primary completion: S
 eptember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacit
 idine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07082452
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554419-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05554419)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing
  the Use of Combination Therapy in Patients With Persistent Low Level Acut
 e Myeloid Leukemia Following Initial Treatment\, The ERASE Study (A MyeloM
 ATCH Treatment Trial)\nEstimated primary completion: 31 December 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05554419
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007312-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Azacitidine: Phase 3 readout est. (NCT07007312)
DESCRIPTION:Azacitidine\, phase 3\, Acute Myeloid Leukemia.\nStudy: Studies
  to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With 
 Untreated NPM1-m or KMT2A-r AML\nEstimated primary completion: November 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007312
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581002-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07581002)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy to Assess Adverse Events and Change in Disease Activity When Intravenou
 s (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and
  IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid L
 eukemia (AML)\nEstimated primary completion: June 2032. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07581002
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2832@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Study
  of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primary
  completion: December 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03013998
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
